News about "Biocon Biologics"

Biocon Raises INR 4,150 Crore via QIP

Biocon has successfully raised INR 4,150 crore through a Qualified Institutions Placement (QIP), with the proceeds set to be primarily used to fund the cash consideration payable to Mylan Inc. (Viatris) for the buyout of its stake in Biocon Biologics, including the repayment of related acquisition debt.

Biocon Biologics | 15/01/2026 | By News Bureau

Biocon Biologics to Showcase Keytruda and Two New Oncology Biosimilars at JPM 2026

Biocon Biologics, the biosimilars arm of Biocon Ltd, is set to introduce three new oncology biosimilars, including a biosimilar of pembrolizumab (Keytruda), at the J.P. Morgan Healthcare Conference 2026 in San Francisco.

Biocon Biologics | 07/01/2026 | By Darshana |  170

Biocon Biologics Secures Global Rights to Hulio

The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.

Biocon Biologics | 23/12/2025 | By News Bureau

Biocon Launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide in Netherlands

Biocon has launched its GLP-1 drug–device combination, Liraglutide, in the Netherlands, where it will be marketed under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.

Biocon Biologics | 15/12/2025 | By News Bureau |  128

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Biocon Biologics | 08/12/2025 | By Dineshwori

Biocon Biologics Reaches Settlement with Amgen, Secures Market Entry Date for Denosumab Biosimilars

Biocon Biologics will introduce both its Denosumab biosimilars — Vevzuo and Evfraxy — in Europe beginning December 2, 2025. Other terms of the settlement with Amgen remain confidential.

Biocon Biologics | 02/12/2025 | By Dineshwori

US FDA Classifies Biocon Biologics' Bengaluru Drug Substance Facility as VAI

The US FDA has classified Biocon Biologics’ Bengaluru drug substance facility as Voluntary Action Indicated (VAI) following an inspection in August–September 2025. The review covers the site’s production of rh-Insulin and biosimilar Pegfilgrastim for the US market.

Biocon Biologics | 29/11/2025 | By Dineshwori |  137

Biocon Clarifies Media Reports on Possible Biocon Biologics Merger

Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.

Biocon Biologics | 14/11/2025 | By Dineshwori |  267

Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth

Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.

Biocon Biologics | 12/11/2025 | By Dineshwori |  327

Biocon Biologics and Civica Launch Private-Label Insulin Glargine in the US

The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialise under Biocon Biologics’ existing marketing approval.

Biocon Biologics | 21/10/2025 | By Dineshwori |  178